- Home
- CGAU vs MDXG Comparison
CGAU vs MDXG Comparison
Compare CGAU & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGAU
- MDXG
- Stock Information
- Founded
- CGAU 2002
- MDXG 2006
- Country
- CGAU Canada
- MDXG United States
- Employees
- CGAU N/A
- MDXG N/A
- Industry
- CGAU Precious Metals
- MDXG Biotechnology: Pharmaceutical Preparations
- Sector
- CGAU Basic Materials
- MDXG Health Care
- Exchange
- CGAU Nasdaq
- MDXG Nasdaq
- Market Cap
- CGAU 1.4B
- MDXG 1.0B
- IPO Year
- CGAU N/A
- MDXG N/A
- Fundamental
- Price
- CGAU $7.10
- MDXG $7.42
- Analyst Decision
- CGAU Buy
- MDXG Strong Buy
- Analyst Count
- CGAU 2
- MDXG 3
- Target Price
- CGAU $12.00
- MDXG $12.00
- AVG Volume (30 Days)
- CGAU 830.3K
- MDXG 809.0K
- Earning Date
- CGAU 05-06-2025
- MDXG 04-30-2025
- Dividend Yield
- CGAU 2.82%
- MDXG N/A
- EPS Growth
- CGAU N/A
- MDXG N/A
- EPS
- CGAU 0.18
- MDXG 0.27
- Revenue
- CGAU $1,208,123,000.00
- MDXG $352,375,000.00
- Revenue This Year
- CGAU N/A
- MDXG $9.23
- Revenue Next Year
- CGAU $7.03
- MDXG $11.49
- P/E Ratio
- CGAU $38.51
- MDXG $27.33
- Revenue Growth
- CGAU 2.88
- MDXG 5.34
- 52 Week Low
- CGAU $5.41
- MDXG $5.47
- 52 Week High
- CGAU $7.82
- MDXG $10.14
- Technical
- Relative Strength Index (RSI)
- CGAU 58.95
- MDXG 59.64
- Support Level
- CGAU $6.31
- MDXG $6.53
- Resistance Level
- CGAU $7.54
- MDXG $7.07
- Average True Range (ATR)
- CGAU 0.25
- MDXG 0.30
- MACD
- CGAU 0.04
- MDXG 0.09
- Stochastic Oscillator
- CGAU 63.82
- MDXG 99.61
About CGAU Centerra Gold Inc.
Centerra Gold Inc a gold mining and exploration company engaged in the operation, exploration, development, and acquisition of gold properties in Asia, North America, and other markets world-wide. The company reportable operating segments are Oksut; Mount; and Milligan Molybdenum. It derives maximum revenue from Oksut segment. Geographically, it operates in Turkey, United States, Canada and Other.
About MDXG MiMedx Group Inc
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.